Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARLIGHT: JR-141 in Mucopolysaccharidosis II
NCT04573023Phase 3Active, not recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Oct 2027
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 12
01
Overview
Phase 3, randomised, single-blind trial of pabinafusp alfa in mucopolysaccharidosis type 2 (3 arms), sponsored by JCR Pharmaceuticals. Primary endpoints: Change in levels of cerebrospinal fluid heparan sulfate from baseline at 53 weeks and Change in the raw scores of cognitive testing measured from baseline (BSID-III) at 105 weeks. Started Feb 2022; status: active, not recruiting.
02
Drugs
pabinafusp alfa
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on NCT04573023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04573023.